Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 3
2007 3
2008 2
2009 6
2010 7
2011 5
2012 2
2014 5
2015 7
2016 4
2017 8
2018 6
2019 6
2020 5
2021 7
2022 3
2023 9
2024 5
2025 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence.
Oviedo-Joekes E, Palis H, Guh D, Marchand K, Brissette S, Lock K, MacDonald S, Harrison S, Anis AH, Krausz M, Marsh DC, Schechter MT. Oviedo-Joekes E, et al. Drug Alcohol Rev. 2018 Jan;37(1):137-146. doi: 10.1111/dar.12573. Epub 2017 Jun 8. Drug Alcohol Rev. 2018. PMID: 28593748 Clinical Trial.
Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling).
Dobischok S, Metcalfe R, Matzinger E, Palis H, Marchand K, Harrison S, MacDonald S, Byres D, Schechter M, Bansback N, Oviedo-Joekes E. Dobischok S, et al. Among authors: oviedo joekes e. Int J Drug Policy. 2023 Feb;112:103948. doi: 10.1016/j.drugpo.2022.103948. Epub 2022 Dec 29. Int J Drug Policy. 2023. PMID: 36586152 Review.
The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review.
Adams A, Blawatt S, Magel T, MacDonald S, Lajeunesse J, Harrison S, Byres D, Schechter MT, Oviedo-Joekes E. Adams A, et al. Among authors: oviedo joekes e. Subst Abuse Treat Prev Policy. 2023 Sep 30;18(1):56. doi: 10.1186/s13011-023-00564-9. Subst Abuse Treat Prev Policy. 2023. PMID: 37777766 Free PMC article.
91 results